Risk factors for second‐line dactinomycin failure after methotrexate treatment for low‐risk gestational trophoblastic neoplasia: a retrospective study

To find risk factors for second‐line dactinomycin failure in patients with low‐risk gestational trophoblastic neoplasia (GTN).

[1]  Xiyan Mu,et al.  Comparison of pulsed actinomycin D and 5‐day actinomycin D as first‐line chemotherapy for low‐risk gestational trophoblastic neoplasia , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[2]  A. Schott,et al.  Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia , 2018, International Journal of Gynecologic Cancer.

[3]  Jubilee Brown,et al.  15years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. , 2017, Gynecologic oncology.

[4]  R. Coleman,et al.  Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia. , 2016, Gynecologic oncology.

[5]  N. Sebire,et al.  Dutch Risk Classification and FIGO 2000 for Gestational Trophoblastic Neoplasia Compared , 2016, International Journal of Gynecologic Cancer.

[6]  A. Swerdlow,et al.  Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jae-Weon Kim,et al.  Trophoblastic Disease Review for Diagnosis and Management: A Joint Report From the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup , 2014, International Journal of Gynecologic Cancer.

[8]  M. Seckl,et al.  Gestational Trophoblastic Tumours: An Update for 2014 , 2014, Current Oncology Reports.

[9]  N. Sebire,et al.  Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  E. Chapman-Davis,et al.  Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia. , 2012, The Journal of reproductive medicine.

[11]  A. Rademaker,et al.  Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy. , 2012, Gynecologic oncology.

[12]  R. Berkowitz,et al.  Molar pregnancy: pathology and management , 2008 .

[13]  C. Sweep,et al.  Early identification of persistent trophoblastic disease with serum hCG concentration ratios , 2007, International Journal of Gynecologic Cancer.

[14]  R. Burger,et al.  Phase II trial of pulse dactinomycin as salvage therapy for failed low‐risk gestational trophoblastic neoplasia , 2006, Cancer.

[15]  A. Mitsuhashi,et al.  Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy , 2005 .

[16]  B. Hancock.  Staging and classification of gestational trophoblastic disease. , 2003, Best practice & research. Clinical obstetrics & gynaecology.

[17]  J. Benedet,et al.  Gestational trophoblastic neoplasia, FIGO 2000 staging and classification , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[18]  G. Rustin,et al.  Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. , 2002, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[20]  G J S Rustin,et al.  The management of high‐risk gestational trophoblastic tumours (GTT) , 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[21]  M. Segers,et al.  Comparison of the Analytical Characteristics and Clinical Usefulness in Tumour Monitoring of Fifteen hCG(-β) Immunoassay Kits , 1985, Annals of clinical biochemistry.